{"id":"NCT03921541","sponsor":"Aeglea Biotherapeutics","briefTitle":"Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency","officialTitle":"PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-10","primaryCompletion":"2023-01-27","completion":"2023-01-27","firstPosted":"2019-04-19","resultsPosted":"2024-11-19","lastUpdate":"2024-11-19"},"enrollment":32,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arginase I Deficiency","Hyperargininemia"],"interventions":[{"type":"DRUG","name":"Pegzilarginase","otherNames":["Co-ArgI-PEG; AEB1102"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Pegzilarginase","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Pegzilarginase Long Term Extension","type":"EXPERIMENTAL"}],"summary":"CAEB1102-300A is a multi-center randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pegzilarginase in patients with ARG1-D. This study will consist of a screening period; a randomized, double-blind treatment period; a long-term extension; and a follow up visit for final safety assessments.","primaryOutcome":{"measure":"Change From Baseline in Plasma Arginine Concentration After 24 Weeks of Treatment","timeFrame":"Baseline through Week 24","effectByArm":[{"arm":"Pegzilarginase","deltaMin":0.244,"sd":1.635},{"arm":"Placebo","deltaMin":0.918,"sd":1.371}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States","Austria","Canada","France","Germany","Italy","United Kingdom"]},"refs":{"pmids":["38292042"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":21},"commonTop":["Vomiting","Cough","Ammonia increased","Constipation","Nausea"]}}